SpeeDx

SpeeDx

Private
Sydney, New South WalesHealthcare & Life Scienceshttps://www.plexpcr.com

Last Round

Series C

Feb 28, 2023

Total Funding Raised

$60.61M

Company Overview

SpeeDx is a molecular diagnostics company that offers an innovative portfolio of multiplex systems for clinical diagnostics, utilizing real-time polymerase chain reaction technology to enable physicians to test for infectious diseases and antibiotic resistance.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

molecular diagnosticsqPCR testsantimicrobial resistanceAMRantibiotic resistance testingSTI testingResistance Guided Therapyin-vitro diagnosticsIVDmultiplex PCRqPCR panelpathogen detectiondiagnostic test kitsrespiratory virus testingmolecular diagnostic solutionslaboratory automation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SpeeDx Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

SpeeDx Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 28, 2023
GrantJul 16, 2021
GrantMay 10, 2021
GrantSep 2, 2020
Series B ExtensionFeb 11, 2020
Series A
Aug 5, 2019

Key People

Founding team and executive leadership

Alison V. Todd AM FTSE

Chief Scientific Officer Founder

Founding Team

Jeremy Stackawitz

Chief Executive Officer

Executive Team

Elisa M.

Chief Technology Officer

Executive Team

SpeeDx Investors

Notable investors and investment history

SpeeDx Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SpeeDx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SpeeDx's valuation, stock price, and market status.

Firmographic Details

HeadquartersSydney, New South Wales
Employee Range86
Year Founded2009
Last FundingFeb 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.